{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:13:51Z","timestamp":1793394831489,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.14283\/jpad.2024.155","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T05:38:24Z","timestamp":1722749904000},"page":"1206-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform"],"prefix":"10.1016","volume":"11","author":[{"given":"H.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping John","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.14283\/jpad.2024.155_bib1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.14283\/jpad.2024.155_bib2","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.14283\/jpad.2024.155_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/awn256","article-title":"Oskar Fischer and the study of dementia","volume":"132","author":"Goedert","year":"2009","journal-title":"Brain"},{"issue":"13","key":"10.14283\/jpad.2024.155_bib4","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.14283\/jpad.2024.155_bib5","article-title":"Tau and Alzheimer's disease: Past, present and future","author":"Iqbal","year":"2023","journal-title":"Cytoskeleton (Hoboken)"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","article-title":"Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015\u20132060) in adults aged \u226565 years","volume":"15","author":"Matthews","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.155_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.14283\/jpad.2023.102","article-title":"Editorial: The State of Alzheimer's Research and the Path Forward","author":"Fillit","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.14283\/jpad.2024.155_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1582-4934.2008.00225.x","article-title":"Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention","volume":"12","author":"Iqbal","year":"2008","journal-title":"J Cell Mol Med"},{"issue":"77","key":"10.14283\/jpad.2024.155_bib12","doi-asserted-by":"crossref","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.14283\/jpad.2024.155_bib13","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.3390\/ijms20225536","article-title":"When Does Alzheimer's Disease Really Start? The Role of Biomarkers","volume":"20","author":"Lloret","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10284","key":"10.14283\/jpad.2024.155_bib14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.14283\/jpad.2024.155_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13533","article-title":"Novel avenues of tau research","author":"Sexton","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2024.155_bib16","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3233\/JAD-170261","article-title":"Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers","volume":"59","author":"Lawrence","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.14283\/jpad.2024.155_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/1567205016666190517121140","article-title":"Biomarkers for Alzheimer's Disease","volume":"16","author":"Guzman-Martinez","year":"2019","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice","volume":"7","author":"Pais","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"key":"10.14283\/jpad.2024.155_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","article-title":"Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging","volume":"78","author":"Ossenkoppele","year":"2021","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.14283\/jpad.2024.155_bib20","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JAD-130203","article-title":"The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study","volume":"36","author":"Molinuevo","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.14283\/jpad.2024.155_bib22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3233\/JAD-170680","article-title":"Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis","volume":"62","author":"Bjerke","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.14283\/jpad.2024.155_bib23","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1002\/alz.12997","article-title":"Alzheimer's Disease Neuroimaging Initiative. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy","volume":"19","author":"Wang","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.14283\/jpad.2024.155_bib24","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/alz.12919","article-title":"CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab","volume":"19","author":"Nisenbaum","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.14283\/jpad.2024.155_bib25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00415-018-9016-3","article-title":"Magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment","volume":"266","author":"Chandra","year":"2019","journal-title":"J Neurol"},{"issue":"11","key":"10.14283\/jpad.2024.155_bib26","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3390\/brainsci13111535","article-title":"Explainable Machine Learning with Pairwise Interactions for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease Utilizing Multi-Modalities Data","volume":"13","author":"Cai","year":"2023","journal-title":"Brain Sciences"},{"issue":"7691","key":"10.14283\/jpad.2024.155_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.14283\/jpad.2024.155_bib29","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment with Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZERALZ Randomized Clinical Trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.14283\/jpad.2024.155_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Ames","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","article-title":"Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment","volume":"15","author":"Mundada","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13195-023-01201-0","article-title":"Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts","volume":"15","author":"Lantero-Rodriguez","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"10.14283\/jpad.2024.155_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","article-title":"Alpha-synuclein: a pathological factor with A\u03b2 and tau and biomarker in Alzheimer's disease","volume":"14","author":"Shim","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-022-01125-1","article-title":"\u03b2-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer's disease","volume":"14","author":"Mohaupt","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.155_bib36","doi-asserted-by":"crossref","first-page":"1256389","DOI":"10.3389\/fnagi.2023.1256389","article-title":"Association between cerebrospinal fluid clusterin and biomarkers of Alzheimer's disease pathology in mild cognitive impairment: a longitudinal cohort study","volume":"15","author":"Wang","year":"2023","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.14283\/jpad.2024.155_bib37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-200065","article-title":"Amyloid-\u03b2 Peptides Disrupt Interactions Between VAMP-2 and SNAP-25 in Neuronal Cells as Determined by FRET\/FLIM","volume":"77","author":"Sharda","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.14283\/jpad.2024.155_bib38","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.14283\/jpad.2024.155_bib39","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"issue":"12","key":"10.14283\/jpad.2024.155_bib40","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.14283\/jpad.2024.155_bib41","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer's disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.14283\/jpad.2024.155_bib42","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1002\/alz.13026","article-title":"Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease","volume":"19","author":"Therriault","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.155_bib43","author":"FDA","year":"2018","journal-title":"Bioanalytical Method Validation Guidance for Industry"},{"key":"10.14283\/jpad.2024.155_bib44","author":"ICH M10","year":"2022","journal-title":"Bioanalytical Method Validation and Study Sample Analysis"},{"issue":"4","key":"10.14283\/jpad.2024.155_bib45","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.155_bib46","article-title":"A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.155_bib47","author":"Therriault"},{"key":"10.14283\/jpad.2024.155_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/alz.079719","article-title":"Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals","author":"Brum","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2024.155_bib49","doi-asserted-by":"crossref","first-page":"e12514","DOI":"10.1002\/dad2.12514","article-title":"Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study","volume":"15","author":"Xiao","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"10.14283\/jpad.2024.155_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology","volume":"81","author":"Ashton","year":"2024","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724006496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:14:32Z","timestamp":1737339272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724006496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2274580724006496"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.155","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}